Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
How do you approach the management of aortitis in patients with ANCA-associated vasculitis?
Related Questions
How would you approach evaluation of a patient with multiple vertebral artery pseudoaneurysms and history of dissection, but without other areas of pseudoaneurysms?
How do you approach the workup and management of isolated orbital inflammatory pseudotumor/granuloma?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
Would you start anticoagulation in a previously heathy patient with a new diagnosis of ANCA vasculitis (+PR3, RPGN, crescents on kidney biopsy) who presented with pancreatitis, splenic and renal infarcts and was also found to have CMV viremia?
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?
Do you offer biosimilar tocilizumab as an alternative to subcutaneous or infusion brand-name tocilizumab when treating GCA?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
Do you send anti-human neutrophil elastase antibodies when you suspect levamisole-induced ANCA vasculitis?
How would you approach treatment duration for a patient with incidentally found large vessel GCA now well controlled on tocilizumab monotherapy?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
